Did BioLife Solutions Run Too Much?

By Chris Lange Published Jun 3, 1:00PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The health care sector has come alive over the past year, headed up by monumental developments within biotech and pharmaceutical companies. BioLife Solutions Inc. (NASDAQ: BLFS) is riding high on this biotech wave. However, there is a question. Has BioLife risen too much?

The jump originally happened when BioLife reported several new customer disclosures on the use of its CryoStor and HypoThermosol biopreservation media products in pre-clinical validation projects and clinical trials. These disclosures took place at the recent International Society for Cellular Therapy (ISCT) conference.

BioLife is developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. It also has a related cloud-hosted biologistics cold chain management app for smart shippers.

In layman terms, this company is capable of shipping and preserving biologic material for cell and tissue based products, even organs. Shipments are controlled via a cloud-hosted app on which they can be tracked and monitored.

Mike Rice, president and CEO of BioLife, commented on the conference and the disclosures:

This ISCT conference was a tremendous success for BioLife by any measure. We learned of several new groups using our biopreservation media products in clinical applications. Traffic at our exhibit was constant throughout the conference, as interest in our new evo smart shipper and cloud hosted biologistex app was very strong. We captured dozens of qualified leads and this event reconfirmed our belief that we have a phenomenal opportunity to help our customer further optimize yield and cost in the manufacturing and delivery logistics of their biologic based therapies, while improving the quality of their distribution practices.

Shares of BioLife were up nearly 60% at $3.15 Wednesday afternoon, in a 52-week trading range of $1.50 to $4.44.

Despite this monumental move, it might appear that BioLife shares are going to give back some of this gain. On the day, the stock hit a new 52-week high at $4.44 and has since slowly retreated. Perhaps this could continue into Thursday.

ALSO READ: 4 Overlooked Winners From ASCO

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.